학술논문
Predictors of clinically significant quality of life impairment in Parkinson’s disease
Document Type
article
Author
Santos García D.; Teresa de Deus Fonticoba; Carlos Cores; Guillermo Muñoz; Jose M. Paz González; Cristina Martínez Miró; Ester Suárez; Silvia Jesús; Miquel Aguilar; Pau Pastor; Lluis Planellas; Marina Cosgaya; Juan García Caldentey; Nuria Caballol; Inés Legarda; Jorge Hernández Vara; Iria Cabo; Luis López Manzanares; Isabel González Aramburu; María A. Ávila Rivera; Maria J. Catalán; Víctor Nogueira; Víctor Puente; María Ruíz de Arcos; Carmen Borrué; Berta Solano Vila; María Álvarez Sauco; Lydia Vela; Sonia Escalante; Esther Cubo; Francisco Carrillo Padilla; Juan C. Martínez Castrillo; Pilar Sánchez Alonso; Maria G. Alonso Losada; Nuria López Ariztegui; Itziar Gastón; Pedro Clavero; Jaime Kulisevsky; Marta Blázquez Estrada; Manuel Seijo; Javier Rúiz Martínez; Caridad Valero; Mónica Kurtis; Oriol de Fábregues; Jessica González Ardura; Carlos Ordás; Luis M. López Díaz; Darrian McAfee; Pablo Martinez-Martin; Pablo Mir; COPPADIS Study Group
Source
npj Parkinson's Disease, Vol 7, Iss 1, Pp 1-10 (2021)
Subject
Language
English
ISSN
2373-8057
Abstract
Abstract Quality of life (QOL) plays an important role in independent living in Parkinson’s disease (PD) patients, being crucial to know what factors impact QoL throughout the course of the disease. Here we identified predictors of QoL impairment in PD patients from a Spanish cohort. PD patients recruited from 35 centers of Spain from the COPPADIS cohort from January 2016, to November 2017, were followed up during 2 years. Health-related QoL (HRQoL) and global QoL (GQoL) were assessed with the 39-item Parkinson’s disease Questionnaire (PDQ-39) and the EUROHIS-QOL 8-item index (EUROHIS-QOL8), respectively, at baseline (V0) and at 24 months ± 1 month (V2). Clinically significant QoL impairment was defined as presenting an increase (PDQ-39SI) or decrement (EUROHIS-QOL8) at V2 ≥ 10% of the score at baseline (V0). A comparison with a control group was conducted for GQoL. GQoL did not change significantly in PD patients (N = 507; p = 0.686) or in the control group (N = 119; p = 0.192). The mean PDQ-39SI was significantly increased in PD patients (62.7 ± 8.5 years old; 58.8% males; N = 500) by 21.6% (from 16.7 ± 13 to 20.3 ± 16.4; p